23
Pharma & HealthcareAvoid
Quant Healthcare
Quant · Direct–Growth · rank #19 of 19 by Smart Score
Data updated
Trailing returns
1 Year
19.9%
+19.2% vs index
3 Years
20.1%
+8.6% vs index
5 Years
—
Since launch
21.7%
Year-by-year performance
2024
+31.9%+16.2% vs index
2025
-3.6%-11.3% vs index
2026
+23.9%+23.0% vs index
Why this score
Quant Healthcare scores 23/100 — #19 of 19 Pharma & Healthcare fund (Avoid). The main drag is its volatility (better than only 3% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Volatility18.22 · 3rd percentile in category
Expense ratio1.62% · 3rd percentile in category
Sharpe ratio0.85 · 25th percentile in category
Alpha2.25 · 16th percentile in category
3Y return20.14% · 38th percentile in category
Sortino ratio1.08 · 23rd percentile in category
Top holdings
1.Zydus Lifesciences Ltd10.25%
2.Divi's Laboratories Ltd.9.92%
3.Aurobindo Pharma Ltd9.83%
4.Glenmark Pharmaceuticals Limited9.38%
5.Glaxosmithkline Pharmaceuticals Ltd8.89%
16 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.